

AMENDMENTS TO THE CLAIMS

IN THE CLAIMS

The following Listing of Claims, in which deleted text appears ~~struck through~~ and inserted text appears underlined, will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-205. (Canceled)

206. (Currently amended) ~~The An oligonucleotide compound of claim 170, wherein said region consisting of 16 monomers, wherein adjacent monomers are covalently linked by a phosphodiester or a phosphorothioate linkage, and wherein the sequence of the oligonucleotide compound is~~ CTCATcatcgCAGC (SEQ ID NO: 130) or CTCATcatcgCAGc (SEQ ID NO: 130), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers.

207. (Canceled)

208. (Previously presented) The oligonucleotide compound of claim 206, wherein said compound is C₅T₅C₅A₅s₅t₅c₅s₅a₅t₅s₅g₅s₅C₅A₅G₅C (SEQ ID NO: 664), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage.

209. (Canceled)

210. (Currently amended) The oligonucleotide compound of claim ~~209~~ 206, wherein said compound is C₀T₀C₀A₀a₀s₀t₀c₀s₀a₀t₀s₀g₀s₀C₀A₀G₀C (SEQ ID NO: 662), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphodiester linkage.

211. (Canceled)

212. (Currently amended) The oligonucleotide compound of claim ~~211~~ 206, wherein said compound is C₅T₅C₅A₅g₅t₅c₅c₅g₅a₅t₅g₅g₅C₅A₅G₅C (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "5" denotes a phosphorothioate linkage.

213. (Currently amended) The oligonucleotide compound of claim ~~170~~ 206, wherein said ~~region~~ compound is CTCAatccatggCAGC (SEQ ID NO: 130) or CTCAtccatggCAGc (SEQ ID NO: 130), wherein uppercase letters denote beta-D-oxy-LNA monomers, lowercase letters denote DNA monomers, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

214. (Canceled)

215. (Currently amended) The oligonucleotide compound of claim ~~244~~ 213, wherein said compound is C₅T₅C₅A₅g₅t₅c₅c₅g₅a₅t₅g₅g₅C₅A₅G₅C (SEQ ID NO: 664), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "5" denotes a phosphorothioate linkage, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

216. (Canceled)

217. (Currently amended) The oligonucleotide compound of claim ~~246~~ 213, wherein said compound is C₀T₀C₀A₀g₀t₀c₀c₀g₀a₀t₀g₀g₀C₀A₀G₀C (SEQ ID NO: 662), wherein uppercase letters denote beta-D-oxy-LNA monomers, lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, the subscript "o" denotes a phosphodiester linkage, and wherein any cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

218. (Canceled)

219. (Currently amended) The oligonucleotide compound of claim ~~248~~ 213, wherein said compound is C₅T₅C₅A₅g₅t₅c₅c₅g₅a₅t₅g₅g₅C₅A₅G₅C (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a

phosphorothioate linkage, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

220. (Currently amended) The oligonucleotide compound of claim 219, wherein said compound is $\text{MeC}_5\text{T}_5^{\text{Me}}\text{C}_5\text{A}_5\text{a}_5\text{t}_5\text{c}_5\text{c}_5\text{a}_5\text{t}_5\text{g}_5\text{g}_5^{\text{Me}}\text{C}_5\text{A}_5\text{G}_5\text{c}$ (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “5” denotes a phosphorothioate linkage, and $\text{MeC}_5^{\text{Me}}\text{C}$ denotes a beta-D-oxy-LNA monomer containing 5-methyl cytosine.

221-224. (Canceled)